Prasol Chemicals Ltd
Incorporated in 1992, Prasol Chemicals
operates in the specialty chemicals industry.[1]
- Market Cap ₹ 4,631 Cr.
- Current Price ₹ 782
- High / Low ₹ 933 / 600
- Stock P/E 44.2
- Book Value ₹ 104
- Dividend Yield 0.00 %
- ROCE 23.5 %
- ROE 20.6 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company has delivered good profit growth of 26.9% CAGR over last 5 years
Cons
- Stock is trading at 7.50 times its book value
- Company has a low return on equity of 14.0% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Specialty Chemicals
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 592 | 896 | 930 | 877 | 1,012 | 1,233 | |
| Sales growth | +51% | +4% | -6% | +16% | +22% | |
| 543 | 763 | 843 | 815 | 925 | 1,092 | |
| Operating Profit | 49 | 133 | 87 | 62 | 88 | 140 |
| OPM % | 8% | 15% | 9% | 7% | 9% | 11% |
| 9 | 7 | 2 | 4 | 3 | 4 | |
| Interest | 12 | 12 | 12 | 11 | 8 | 8 |
| Depreciation | 13 | 17 | 19 | 21 | 23 | 25 |
| Profit before tax | 34 | 111 | 58 | 34 | 59 | 112 |
| Tax % | 26% | 26% | 17% | 46% | 27% | 26% |
| 25 | 83 | 49 | 18 | 44 | 83 | |
| EPS in Rs | 4.33 | 14.24 | 8.38 | 3.13 | 7.51 | 14.33 |
| Dividend Payout % | 2% | 0% | 0% | 10% | 4% | 8% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 10% |
| TTM: | 22% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 27% |
| 3 Years: | 20% |
| TTM: | 92% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 18% |
| 3 Years: | 14% |
| Last Year: | 21% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 12 | 12 | 12 | 12 | 12 | 12 |
| Reserves | 177 | 251 | 298 | 314 | 356 | 437 | 606 |
| 162 | 162 | 186 | 83 | 102 | 111 | 69 | |
| 207 | 253 | 193 | 218 | 254 | 280 | 384 | |
| Total Liabilities | 550 | 677 | 688 | 626 | 723 | 839 | 1,071 |
| 267 | 293 | 291 | 326 | 326 | 314 | 318 | |
| CWIP | 20 | 25 | 60 | 22 | 21 | 47 | 70 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 263 | 360 | 338 | 278 | 376 | 478 | 683 | |
| Total Assets | 550 | 677 | 688 | 626 | 723 | 839 | 1,071 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| 20 | 81 | 29 | 116 | 22 | 49 | |
| -41 | -42 | -54 | -12 | -26 | -42 | |
| 14 | -12 | 11 | -115 | 10 | 0 | |
| Net Cash Flow | -7 | 28 | -13 | -11 | 7 | 7 |
| Free Cash Flow | -27 | 33 | -23 | 97 | -0 | 11 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 52% | 79% | 47% | 194% | 43% | 57% |
Ratios
Standalone / View Consolidated
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 90 | 71 | 66 | 67 | 71 | 83 |
| Inventory Days | 68 | 85 | 74 | 58 | 79 | 67 |
| Days Payable | 143 | 133 | 91 | 99 | 102 | 91 |
| Cash Conversion Cycle | 15 | 22 | 49 | 25 | 48 | 58 |
| Working Capital Days | -25 | -7 | 5 | 14 | 28 | 42 |
| ROCE % | 32% | 15% | 11% | 15% | 24% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Investor/analyst 1x1 and group meetings on 25 Nov 2026 in Mumbai.
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
- Announcement Under Regulation 30 (LODR)-Earnings Call Transcript
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
- Newspaper Advertisement for Unaudited Standalone Financial Results for the Quarter and Half year ended September 30, 2026
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- Q2 FY27 earnings conference call recording hosted on company website on November 3, 2026.
Concalls
-
Nov 2026Transcript PPT REC
-
Oct 2026Transcript PPT REC
Business Overview[1]
The company is primarily engaged in manufacturing acetone- and phosphorus-
based specialty chemicals, as well as
other customised specialty chemicals
with differentiated and complex chemistries.
Its products are used across a diversified set
of industries, including performance chemicals, paints, inks, construction and adhesives (PICA), pharmaceuticals, agrochemicals, and home and personal care. This diversified end-use exposure reduces its dependence on any single industry.[2]